

We thank all the reviewers for their suggestions and the time they took to critically review the manuscript.

Reviewer #1: The manuscript by Velkova et al., describes the identification and functional characterization of the *C. elegans* ortholog of RMI2 (RMIF-2), a member of the BTR complex critical for recombination processing. The authors isolated RMIF-2 as an interactor of RMI1 (RMH-1), another member of BTR, through pull downs; RMIF-2 contains an OB fold, a key feature of the mammalian protein. Analysis of steady state protein levels and localization reveal that similar to the mammalian homolog, RMIF-2 is required for the stability of RMH-1 and for the recruitment of the other members of the BTR complex to recombination foci. Genetic and cell biological assays go on to compare the phenotypes of *rmif-2* and *rmh-1* and reveal both similarities and differences. Most strikingly, analyses of cytological markers of crossovers reveal that unlike other members of the BTR complex, including *rmif-2*, MSH-5 foci are completely absent in the *rmh-1* mutant; however, the COs generated in *rmh-1* (and *rmif-2*) mutants are dependent on MSH-5 (and COSA-1). Further, the crossover landscape is altered in the mutants and both are important for restricting heterologous recombination, although *rmh-1* mutants have a more severe phenotype than *rmif-2* mutants with respect to heterologous recombination. Overall, this is an important study that identifies a new member of the BTR complex in a system that allows for in depth analysis of the meiotic recombination phenotype.

As detailed below, statistics need to be added for several of the analyses. In addition, the following should be addressed in a revised manuscript:

1. Please consider changing the title. I recommend something like: *Caenorhabditis elegans* RMI2 (RMIF-2) and RMI1 (RMH-1) have both overlapping and distinct meiotic functions within the BTR recombination complex

Our response: We want to thank Reviewer #1 for the constructive suggestions and ideas throughout the revision process. We have now changed the title.

2. In the author summary, please define heterologous recombination or remove to more generally tell the audience the significance.

Our response: This has now been corrected.

3. Line 71: "crossing overs" should be "cross overs"

Our response: This has now been corrected.

4. Line 110: Please add, "In mammalian cells, . . ."

Our response: This is now corrected.

5. Lines 124-125: the authors write " . . . , indicating that *rmif-2* functions not just as RMH-1 stabilizer for all its activities in the germline." The way this is written implies to me that *rmif-2* has additional functions, while the data indicates that it is *rmh-1* that has additional functions.

Our response: We have now rephrased this.

6. Table 2: Please include statistics – I don't know whether 40% is different than 50%, for example.

Our response: We have now included the statistics in the table and legend.

7. Line 152: The authors indicate that there is "robust" IP between RMH-1 and RMIF-2. Perhaps you can quantify how much of RMH-1 is coming down with RMIF-2 to substantiate this claim, based on the images shown, I am not convinced it is "robust".

Our response: (also see Reviewer 2, comment 2) We have now repeated the IP experiment, using an additional control (*ha::rmh-1*), as suggested by reviewer #2, and provided a cleaner Western blot for the co-IP-ed HA and identified with an asterisk the unspecific bands on the FLAG Western blot.

For sure the IPs repeatedly pulled down RMIF-2 when analyzed with mass spectrometry.

8. In Figure legend 1, the authors say that late RMIF-2 pachytene foci are brighter than mid-pachytene. Based on the image, it is not clear to me whether the foci are brighter. Did the authors quantify intensity? Is there a statistical difference?

Our response: We have now reformulated the sentence to show that we aimed to make the distinction that the late pachynema foci of RMIF-2 are reduced in numbers in comparison to the early and mid pachynema as shown in the quantification on Fig 1D. We did not intend to distinguish them in intensity.

9. Figure 2: Is there a statistical difference in RAD-51 foci between the different mutants as indicated in the results section?

Our response: We have now included detailed statistical analysis of the RAD-51 quantifications in a supplementary materials file (S2), comparing different genotypes to each other as well as specific zones with a specific number of foci present. Analysis can also be found in the text.

10. Line 230: The authors indicate that in the absence of RMIF-2, there is "none" RMI-1 in the insoluble nuclear fraction; please change to below levels of detection.

Our response: This is now corrected.

11. Figure 4: The significance of the paper rests on the differential phenotypes of *rmi-1* and *rmif-2*. I realize that *rmi-1* has been previously analyzed by this group, but it would be much easier for the reader if more of the analysis of *rmi-1* was included so that it can be directly compared with *rmif-2*. This was particularly noticeable with respect to the analysis of localization of the different BTR complex members. I would also like to see the quantification of TOP-3 foci in the *rmif-2* mutants in Fig4D.

Our response: We have now included further *rmh-1* analysis in the text for direct comparison to the mutants discussed. We also quantified the TOP-3 foci in the *rmif-2* mutant, which can be found in the updated Fig 4.

12. Line 260 title: Please consider changing the subtitle.

Our response: This has now been corrected.

13. Line 274: the sentence is awkward. "... accumulation was delayed and fewer foci were observed . . ."

Our response: This has now been corrected.

14. I found the analysis of *rcq-1* distracting and would recommend either expanding to more clearly state the significance, or removing.

Our response: Thank you for your suggestion, we have now removed the analysis of *rcq-1* as Reviewer #2 (comment 6) had a similar suggestion.

15. Did the authors analyze *him-6; rmh-1*? This would be important for comparing with the phenotype of *rmif-2; him-6*.

Our response: Thank you for the suggestion. We have included in our analysis the already published knowledge on *rmh-1; him-6* (Jagut et al, 2016) as well as conducted a RAD-51 foci quantification in the double mutant in comparison to controls as seen on Figure 2.

16. The recombination mapping needs statistics, including analysis of interference.

Our response: We have now corrected this. Detailed analysis can be found in Figure 7 and its legend as well as the text. Since we do not have a good marker to make the difference between Class I and II COs, we cannot really make statements on interference.

17. Line 417 problem with sentence.

Our response: This has now been corrected.

Overall, I think this is an important study that with the addition of statistics and the inclusion of additional data comparing *rmi-1* and *rmif-2* would make a substantial contribution to our understanding of the role of different members of the BTR complex in meiotic recombination.

Reviewer #2: In their manuscript, the authors identified RMIF-2, a new member of the conserved BTR complex in *C. elegans* nematodes. The new protein does not have significant sequence homology to RMI2, a conserved member of the complex. However, it functionally behaves as a member of the complex. The authors then go on to define the contributions of RMIF-2 to the meiotic prophase functions of the BTR complex, and find that it has both overlapping and unique functions with other members of the complex. The BTR complex is crucial for the maintenance of genomic integrity, DNA repair, and several key meiotic functions. In addition, the biochemical activities of the BTR complex, and some of its members, have been

characterized extensively. However, the consequences of specific genetic perturbations are challenging to parse out. Some of the complexity stems from the fact that members of the complex play different roles when acting in the BTR complex and outside it. Many times, with opposite effects. Hence, the exact functional contributions of the complex and its members to the biological processes it is involved in are not well understood.

Insight in the worm BTR complex would be of interest to the worm meiosis community, as well as to the many scientists working on pathways that maintain genome integrity. The main contributions of the manuscript are the identification of RMIF-2, and a high-quality characterization of the consequence of its deletion on key meiotic processes. Frustratingly, however, the manuscript does little to shed light on the specific functions of the BTR complex and its members.

For this work to be a significant contribution to the field it would require further mechanistic insight into the function of the BTR complex. This could come in the form of better characterization of some of the unexpected genetic interactions presented. For example, the synthetic sterility of double mutant *rmif-2 him-6*; or the surprising effect of *rmh-1* deletion on the localization of MSH-5. Ideally, this additional analysis could be synthesized to a model diagram that would tease out the different functions that the manuscript invoked. In addition, key issues relating to quantification of cytological data, to the co-IPs, and to statistical analysis have to be resolved.

Major points are listed below:


1. Lack of MSH-5 foci upon *rmh-1* deletion (Fig. 6A): If true, that is perhaps the most interesting finding of this manuscript. However, it warrants further scrutiny. As it stands, it is in apparent contradiction to near complete co-dependency of RMH-1 and RMIF-2 for localization (Fig. 3). If RMIF-2 is required for RMH-1 localization, then why do they have different phenotypes with regard to MSH-5 localization? In addition, since many chiasmata do form in the *rmh-1* mutant (Fig. 2A), the localization data would suggest these are MSH-5-independent events. That latter conclusion would be very interesting if true, but genetically, the chiasmata in *rmh-1* mutants appear to be mostly MSH-5 dependent (Fig. S2A). Alternatively, MSH-5 can act without forming foci. In sum, this result has to be cleaned up. First of all verified: different tag/antibody for MSH-5 should be used, and evidence of the correct genotype (i.e., sequencing of the tag being used) should be provided. Assuming this result is corroborated, follow up is necessary to explore its implications; namely, do MSH-5-independent COs form in *rmh-1* mutants?

Our response: We want to thank Reviewer #2 for the constructive suggestions and ideas throughout the revision process. We agree that the finding that in the *rmh-1* mutant background MSH-5 foci cannot be detected is an interesting finding, having in mind that the RMH-1 and RMIF-2 localization into foci is mutually dependent. Indeed, most chiasmata in *rmh-1* seem to be MSH-5 dependent, however, as increased fragmentation is observed in the triple mutant *rmh-1; cku-70; msh-5* diakinesis counts that we now have added to the analysis (S4 Fig 4A and B), some of the *rmh-1; msh-5* undefined structures seem to be dependent on the activity of the NHEJ pathway. Indeed, when we got the


result of MSH-5 localization in *rmh-1* we first thought: something must be wrong with that strain—and we re-genotyped the strain several times. In addition, we have now re-verified the tag and strain correctness through genotyping via PCR and sequencing, which can be seen below as sequencing alignments and PCR agarose gel images.

Re-Sequencing data for *gfp::msh-5* and *rmh-1(jf54)*; *gfp::msh-5* to confirm the GFP-tag insertion.





Genotyping via PCR of GFP-tag and *rmh-1(jf54)* (PCR+restriction) to verify strain legitimacy.



2. The co-IPs suffer from some technical issues. In Fig.1 there are several bands that shouldn't be there in the untagged input lane. The IP band in the FLAG blot is also hard to see. I recommend this blot be repeated, and all non-specific bands be clearly labelled. A strain with only HA::RMH-1 would be a good control to include in this experiment as well. In Fig. 3C&F: the quantifications don't seem to match the blots. The faint bands in ha::rmh-1; rmif-2 NS fraction (panel B) appears as almost zero in the quantification. Likewise for the rmh-1; rmif-2::ha in panel E - the faint band yields almost the same quantification as the untagged lane, although they appear different in the blot.

Our response: We have now repeated the IP experiment from Fig. 1 and provided a new Western blot. As suggested, we have added the *ha::rmh-1* control and labeled the unspecific bands. In Fig. 3E now the blot matches the quantification order and we also updated the column graphs on Fig 3C and 3E to show the single value points quantified. In fact, the quantification is derived from several W-blot— but we show now a blot, where the average quantification is better reflected in the displayed blot.

3. Figures 7 and 8 lack statistical analysis for significance. That is essential. In Fig. 7 the results are challenging to interpret; why are the number of events shown, rather than their fraction? I would recommend that Fig. 8 include a diagram of the genetic assay being used. This is not a commonly used assay and it is not trivial to follow.

Our response: We have now corrected this and added detailed statistical analysis of Fig. 7 in the text and legend. We have also included a schematic representation of the chromosome inversion (Fig. 8A) on which the heterologous recombination assay is based and cited again the publication where this assay had been described in detail.

4. Figure 4B: Immunofluorescence is not inherently quantitative since many of the steps involve non-linear amplification. Unless sufficient controls are added, quantitative comparisons of intensity between different genotypes should not be carried out. At the very least, the gonads from the two genotypes need to be imaged on the same slide, and even then, quantitative comparison should be taken with a grain of salt. Alternatively, the linearity of the intensity measurements should be addressed by measuring it in a condition of heterozygosity for the tag (it should go down by ~50%). In this specific case, an additional issue is that even if the quantitation is taken at face value, the main difference seems to be not between the average intensities, but between the seemingly bimodal distribution for *ha::him-6* and the only dim foci for *rmif-2* deletion. A related issue plays out in Fig. 6B. If the difference in ZHP-3 staining is indeed so dramatic, it should be addressed by some form of semi-quantitative imaging, and discussed further in the text.

Our response: We agree that major conclusions from quantifying immunofluorescence signal are difficult to be drawn. In the context here, it is not possible to image two different genotypes on the same slide. We understand the concern and critique of the reviewer and we want to make clear that the distinction we wanted to point out with the *him-6::ha* quantification is that in the *rmif-2* mutant HIM-6 still manages to concentrate into foci. However, they are different than in the WT. This is also true for the *rmh-1* mutant, where HIM-6 foci were previously shown to be present in pachynema but seemed smaller and fainter than in the WT (Jagut et al., 2016). Moreover, we want to point out that the intensity signal for different gonads/genotypes are adjusted using the same Maximum intensity projections of images deconvolved with the same settings, and the signal quantification was meant to corroborate what is already visible from the pictures (weak foci, which are detectable). We moved this part from the main figure to a supplementary figure S3.

5. Table 1: All proteins identified should be displayed. It is not clear from the text whether RMIF-2 is the 5th most abundant one or not. But either way, the results of this IP/mass- spec experiment should be shown in their entirety.

Our response: We have now corrected this. We have added a supplementary file (S1) with the complete list of RMH-1 interacting proteins as determined by affinity purification mass spectrometry and updated Table 1.

6. Table 2: As noted above, some of the genetic interactions shown here should be explored further, as they might supply mechanistic insight that is currently missing in the paper. Most notably, the near synthetic sterility between *him-6* and *rmif-2*. At the minimum, other double mutant in the BTR complex should be analyzed, and the double mutant *him-6 rmif-2* should be analyzed cytologically to address the source of this near sterility. Second, the result regarding *rcq-1* (both here and in the text) is currently superficial and adds little to the conclusions. I would recommend removing it altogether, or alternatively, expanding and contextualizing it better. Finally, SD (or other indication of distribution) should be provided for the male percentage data.

Our response: We have now included detailed analysis of the *rmif-2 him-6* double mutant with regard to diakinesis chromosome counts, RAD-51 foci quantification throughout pachynema and viability analysis (Fig 2A, 2B, 2C and Table 2). We have removed the *rcq-1* analysis as suggested by reviewer #1 as well. We have also corrected the viability table with the SD values for the male percentage data.

Reviewer #3: The paper by Velkova et al identifies the *C. elegans* functional homolog of RMH-2 and describes its role in meiosis. The work is well done, and is convincing that RMIF-2 is indeed the functional homolog of RMH-2. Overall, a complex picture of the role of the BTR complex emerges. The complex is essential for chiasma formation, crossover regulation and preventing illegitimate recombination. RMIF-2 may not be completely essential for all of these functions, but the *rmif-2* mutant is phenotypically close enough to *rmh-1* to suggest it mostly is. The paper could benefit from some additional analysis that will address some unclear relationships between RMH-1 and RMIF-2 and the outcome of DSB repair as well as some textual/presentation changes, according to my comments below.

Major comments

1) Some statistical analysis is missing or just presented in the figure legend in a way that makes it hard to follow (table 2, Figure 2C, Figure 5, Figure 6AD, Figure 7, Figure 8 and Figure S3). The word "significant" is sometimes used without showing the p values. It's important to add p values in the figures and tables, so it will be easily accessible to the reader. Since there are many comparisons to be made, it may be advisable to focus on the more relevant statistical comparison: 1) all mutants to wild type 2) double mutants to the representative single mutants, 3) *rmf-1* to *rmif-2*.

Our response: We want to thank Reviewer #3 for the constructive suggestions and ideas throughout the revision process. We have now corrected these issues. We have included statistical analysis for table 2

in the legend, for Fig. 2C in a new supplementary file S2 and in the text, in the figure and legend for Fig. 5, in the figure and figure legend for Fig. 6AD (now Fig 6B), in the figure and legend of Fig. 7 (now combined with old Fig S3), in the figure and legend of Fig. 8.

2) Performing these statistical analyses will be needed to support some of the claims made. In addition, it will help to clear if *rmif-2* and *rmf-1* show complex genetic interaction (epistatic relationship (duplicate recessive epistasis) in some assays (emb, DAPI bodies #, % males?) and additive in others (brood size, RAD-51 foci)), or if the perceived additive interaction may not hold following statistical analysis (all recessive epistasis). If indeed after statistical analysis it is still clear that there is different genetic interaction between the mutants for different assays, the authors need to explain why they show epistatic relationship in some assays and additive in others, despite the assays reflecting similar meiotic processes. Thus far they just state that some of the functions are not interchangeable (line 323-348) but it's not clear why we get a mixed bag and the relations to specific phenotypes.

Our response: Through the statistical analysis we could now address these differences in the text.

3) I have some issues interpreting Figure 7 and Figure S3 and thus the conclusions driven from this figure. In ref 19 (Jagut et al. 2016), *rmh-1* mutants show no statistically significant elevation in DCO numbers, while here they may do (X4 elevation, Figure S3) but in the absence of statistical analysis we don't know if this is significant. In addition to a statistical comparison of wild-type to mutant, it will be important to know if the n values in these assays can identify one missing crossover on one of the six chromosomes. In *rmif-2* only a single crossover is missing (7 DAPI bodies), but if this is a random chromosome and only one chromosome is interrogated by SNPs, the expected crossover category should only drop by 1/6. If n values are low, this may not be detected. Running the observed data vs. the "expected" number of crossovers based on loss of one crossover per 6 chromosomes and the n values of the experiment, would be helpful.

Our response: We have now added a detailed statistical analysis to the recombination assay and show the differences between the theoretical recombination frequencies, and the observed recombination frequencies in WT and *rmif-2*, *rmh-1* mutants. Please refer to Fig 7 and its legend as well as to the text for the statistical analysis of recombination frequency over the total amount of animals, the statistical analysis of recombination frequency between specific SNPs and analysis for the change in CO distribution between WT and mutants. In our SNPs analysis we don't really cover the entire length of the chromosomes and it might be possible that we miss some of the COs occurring, for example, at the very ends. On the other side, the 7 DAPI bodies could be the result of a premature dissociation of one bivalent after the CO designation so it is difficult to make a proper quantification/prediction.


4) Line 330-332: It is stated that in *rmh-1*; *rmif-2* double mutate "six aberrant bodies that differed markedly from the well-shaped bivalents in the wild type"

it's begging to ask if these DAPI bodies are formed by NHEJ events. How many DAPI bodies are observed in *rmh-1*; *rmif-2*; *ku* mutants?

Our response: We have now constructed the triple mutant *rmh-1*; *cku-70*; *rmif-2* and DAPI body counts data can be found in Fig 2A and 2B.

5) Line 330-332 and figure 2AB. Can the authors confirm in another way (e.g., staining for axis proteins) that aberrant DAPI bodies are observed in the *rmh-1*; *rmif-2* double mutants but not *rmif-2* single mutants? This is also related to Jagut et al (ref19) observing that *rmh-1* mutants show abnormal bivalent structure- I think it will be important to examine if *rmif-2* has any "abnormal bivalents".

Our response: Using immunofluorescence with antibodies against HTP-3 (marking both short and long bivalent arms) and HTP-1 (marking only the long arm) we tried to examine the presence of abnormal bivalents in *-1* oocytes. We concluded that this assay is highly variable and is difficult to quantify. Please find below a representative image of animals from WT, *msh-5*, *rmh-1*, *rmif-2*, *rmh-1*; *msh-5* and *rmh-1*; *rmif-2* stained for anti-HTP-3 (in green) and anti-HTP-1 (in red). As we saw already a huge amount of variability in the wild type, we are cautious about any conclusions drawn from such experiment.



6) Assuming that reduction of crossovers is not observed (but could have been detected, point #2), it requires better discussion. If crossover frequencies are not reduced, why are there univalent? I don't see an explicit explanation to this the discussion. How is their explanation of these

observations with *rmif-2* connected to how the phenotype of *rmi-1* mutants is explained in ref 19, destabilization of chiasma after crossover are formed?

Our response: This has now been discussed in the text.

Minor comments

7) Line 99-101 "Loss of function of both *Rmi1* and topoisomerase 3 leads to meiotic catastrophe, due to persistent joint molecules that are resistant to cleavage by resolvase" How can the nulls act synergistically if they are in the same complex? Maybe indicate that they also have separate function?

Our response: We addressed this in the text.

8) Line 252- I don't see much difference between background foci of Top3 and background foci of other proteins in BTR mutants. However, Top3 residual staining in the *rmif-2* mutants is described as "cytoplasmic aggregates", when this word is not used to describe other residual/background staining. Are these really bigger, or show different characteristics that I can't see? I think the word "aggregate" is a bit too loaded, unless there is a reason to call them so...

Our response: This has now been rephrased. We did not want to imply a unique type of background foci but rather lack of proper TOP-3 localization into nuclear foci.

9) Line 260: I would not call it "expression profile" but "localization" since "expression" makes the reader expect to see mRNA/RT-PCR or western blot data.

Our response: This has now been corrected.

10) Line 272- I don't see how it is "contrary to our expectations " in figure 2A: *rmif-2* had ~7 bivalents and *rmh-1* has ~8.5. That should translate to a reduction of 1 crossover site (5 crossovers) in *rmif-2* and 2 in *rmh-1* (3-4 crossovers) and this is very close to what is observed with *COSA-1* at zone 7: *rmif-2* had 5 crossovers/*COSA-1* and *rmh-1* has 3/*COSA-1*.

Our response: This has now been corrected.

11) Line 277 "*rmh-1* 3 (\pm 1.4 SD)", to "*rmh-1* (3 \pm 1.4 SD)"

Our response: This has now been corrected.

12) Line 315-320 and Figure S2A. The experiment counting bivalent numbers in *rmh-1*; *msh-5* (S2A) is interesting. I agree, that it shows that many bivalents in *rmh-1* mutants are formed by class I crossover. Except, I would not say "largely" in "the joint structures seen in diakinesis were indeed largely dependent on *MSH-5*.", since the phenotype of the double mutant is essentially in the middle between *rmh-1* and *msh-5* (10.8 is between 8.5 and 12). These data therefore shows that about half of the remaining physical attachments between chromosomes in *rmh-1* mutants are not class I crossovers. It is unclear if these are other types of crossovers or NHEJ events. Can *rmh-1*; *msh-5* mutants be analyzed for bivalent numbers to resolve the question if NHEJ is involved? Are the bivalents observed in *rmh-1*; *msh-5* "abnormal bivalents"?

Our response: We have now constructed the triple mutant *rmh-1; cku-70; msh-5* and the analysis of DAPI body counts can be found in S4 Fig4A and 4B and in the text. Concerning the question about the abnormal bivalents please refer to the answer to Reviewer 3, question 5.

13) Line 327: "Strikingly, we observed that in the *rmh-1; rmif-2* double mutant, embryonic lethality increased to 56%" reading this it sounds like the double mutant showed a more severe phenotype than both single mutants, while it actually did not. I suggest to remove "Strikingly" (because it is what is expected) and add something like ", levels similar to *rmh-1* mutants"

Our response: This has now been corrected.

14) Line 364:" For chromosome IV, the difference was less pronounced" I don't think IV differences are significant (also related to comment #1-2). If so, it cannot be states that there is a difference at all.

Our response: This has now been corrected. Please refer to the added statistical analysis in Fig 7. and its legend.

15) Line 402-406: "In contrast, the reduced number of univalents in *rmif-2* mutants might be due to the higher recombination rates in this background,...The extra crossovers in *rmif-2* mutants might connect the univalents, which likely arise through the absence of a pro-crossover activity that is shared by *RMH-1* and also seems to be lacking in *him-6* mutants" I found this sentence hard to read. If the authors like to propose that DCO reduce number of bivalents they need to support this better. This is also related to comment #6.

Our response: We meant to say that extra crossovers in *rmif-2* may counteract the univalent formation which are caused by a lack of crossover activity.

16) Line 406-408: "Thus, the reduced number of univalents in *rmif-2* mutants might be linked to their lower rate of embryonic death compared with *rmh-1* mutants" I would phrase it the other way around, since the univalents cause the death.

Our response: This has now been corrected.

17) Line 408-409: "fact, a degree of redundancy between *RMH-1* and *RMH-2* (both being *RMI1* homologs) is indicated by the embryonic lethal phenotype of the double mutant" *RMH-2* gets into the discussion out of the blue (I think the reader needs a reminder, since it was only mentioned lastly in the introduction). In addition, it is not clear to me if the double mutant *rmh-1;rmh-2* is inviable (stated in ref 19), or that it is viable but produced dead embryos (here?)- which is true? Please clarify.

**Our response: We have now corrected this in the text.
The double mutant is zygotic lethal.**

18) Line 419-423: the lack of *MSH-5* localization in *rmh-1* mutants, but the demand for its activity (DAPI bodies in *rmh-1; msh-5*) may simply imply that *MSH-5* is localized to crossover sites in *rmh-1*, but the levels are too low to

detect. I don't know if that was what the last sentence means to say...

Our response: This has now been rephrased.

19) Line 422-423: "Moreover, the formation of joint chromosome structures in *rmh-1* depends on *msh-5*, so a future challenge will be to elucidate this RMH-1-specific activity." It partially depends.

Our response: This has now been corrected.

20) line 428-429: I don't see why different activity is required since throughout the paper, despite the overwhelming resemblance of phenotypes between *rmh-1* and *rmif-2*, *rmif-2* always seem to be very slightly better, suggesting some BTR active complex can form without *rmif-2*.

Our response: This is rephrased now and also addressed in the discussion.

21) line 435-437: "The delayed formation and reduced numbers of MSH-5 and COSA-1 foci that we detected in *rmif-2* mutants argue that extra crossovers arising through the lack of such activities are not marked by MSH-5 and are likely class II crossovers, which are usually resolved by non-canonical resolvases." This implies that the # of MSH-5 and COSA-1 foci in *rmh-1* mutants is lower than the numbers expected from counting # of DAPI bodies. In *rmif-2* mutants there are 7 DAPI bodies = 5 crossovers, and there are 5 COSA-1 foci and 5 MSH-5 foci, so I don't see the need to call for other crossover pathways. In my opinion the only support for class II crossovers may come from the SNP data in comparison to COSA-1/MSH localization.

Our response: Yes, this is correct.

22) line 444 "In contrast, the rate of heterologous recombination is lower in *rmif-2* mutants than in *him-6* or *rmh-1* mutants" please add citation for heterologous recombination rates in *him-6*.

Our response: This has now been corrected.

Figures

23) Figure 2A- It's not clear which ones of the four most right genotypes are significantly different from each other. I would assume *spo-11* and *rmif-2;spo11* are not but *spo11* and *rmih-1;rmif-2* are...

Our response: This has now been corrected and incorporated in an additional file S2 with all raw and statistical analysis for the RAD-51 foci quantification as well as discussed in the text.

24) Figure 3C and F- could the data points be shown?

Our response: This is now corrected and data points are shown for each replicate.

25) Figure 4D- This was quantified using different zones than the rest of the data. Where are that zones in the germline? I see the description in the figure legend but maybe a cartoon/image like Figure 2C will help.

Our response: This has now been added. An image of the different zones is now found in Fig. 4C and the quantification is in Fig. 4D.

26) Figure 7A- please add n values (not only in present them in the text)

Our response: This has now been added, please refer to Fig. 7 and its legend.

27) Is Figure 8B a single data point? If yes, I don't believe that this can be presented in this way. It looks like 8B is the result of the calculation in the right-most column in 8A. If so, it just needs to be incorporated to figure 8A, which now can be presented as a table and not as a figure...

Our response: This has now been corrected. Please refer to Fig. 8.

28) Table 1- please use RMIF-2 instead or in addition to Y104H12D.4

Our response: This has now been corrected.

29) I would suggest adding a cartoon of RMIF-2 compared to mouse/human RMI2 so the overall size and the position of the OB-fold domain can be compared.

Our response: This has now been added. Please refer to Fig. 1A.